Cited by 432Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

Open access

Peng, Weiyi, Liu, Chengwen, Xu, Chunyu, Lou, Yanyan, Chen, Jieqing, Yang, Yan, Yagita, Hideo, Overwijk, Willem W., Lizée, Gregory, Radvanyi, Laszlo, Hwu, Patrick·2012·Cancer Research

DOI 10.1158/0008-5472.can-12-1187PMC PMC3476734

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Adoptive cell transfer (ACT) is considered a promising modality for cancer treatment, but despite ongoing improvements, many patients do not experience clinical benefits. The tumor microenvironment is an important limiting factor in immunotherapy that has not been addressed fully in ACT treatments. In this study, we report that upregualtion of the immunosuppressive receptor programmed cell death-1 (PD-1) expressed on transferred T cells at the tumor site, in a murine model of ACT, compared with its expression on transferred T cells present in the peripheral blood and spleen. As PD-1 can attenuate T-cell-mediated antitumor responses, we tested whether its blockade with an anti-PD-1 antibody could enhance the antitumor activity of ACT in this model. Cotreatment with both agents increased the number of transferred T cells at the tumor site and also enhanced tumor regressions, compared with treatments with either agent alone. While anti-PD-1 did not reduce the number of immunosuppressive regulatory T cells and myeloid-derived suppressor cells present in tumor-bearing mice, we found that it increased expression of IFN-γ and CXCL10 at the tumor site. Bone marrow-transplant experiments using IFN-γR-/- mice implicated IFN-γ as a crucial nexus for controlling PD-1-mediated tumor infiltration by T cells. Taken together, our results imply that blocking the PD-1 pathway can increase IFN-γ at the tumor site, thereby increasing chemokine-dependent trafficking of immune cells into malignant disease sites.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-1187

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Self-citation
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Self-citation

Show all 41 references

Research works printed but not linked: 1

Laszlo, 2010, Adoptive T cell therapy for metastatic melanoma: the MD Anderson experience, J Immunother, 33, 863

Sorted by citations

Items 101–200 of 432

PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses
Medina, P. J., & Adams, V. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1714 · Cited by 90
Immune-priming of the Tumor Microenvironment by Radiotherapy
Shahabi, V., Postow, M. A., Tuck, D. P., & Wolchok, J. D. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182868ec8 · Cited by 86
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
Nonomura, Y., Otsuka, A., Nakashima, C., Seidel, J. A., Kitoh, A., Dainichi, T., Nakajima, S., Sawada, Y., Matsushita, S., Aoki, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248327 · Cited by 83
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
Wu, W., Liu, Y., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01166-3 · Cited by 83
Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1–Mediated Immune Suppression
Haile, S. T., Dalal, S. P., Clements, V. K., Tamada, K., & Ostrand‐Rosenberg, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202777 · Cited by 83
Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
Sawada, Y., Yoshikawa, T., Shimomura, M., Iwama, T., Endo, I., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2737 · Cited by 78
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology
Qi, T., McGrath, K. V., Ranganathan, R., Dotti, G., & Cao, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114421 · Cited by 80
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions
Wang, J., Xie, T., Wang, B., William, W. N., Heymach, J. V., El‐Naggar, A. K., Myers, J. N., & Caulı́n, C. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0108 · Cited by 78
New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine
Xu, H., Lin, S., Zhou, Z., Li, D., Zhang, X., Yu, M., Zhao, R., Wang, Y., Qian, J., Li, X., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01032-x · Cited by 78
Trial Watch
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24238 · Cited by 78
Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity
Hao, D., Liu, J., Chen, M., Li, J., Wang, L., Li, X., Zhao, Q., & Di, L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3862 · Cited by 77
Role of Type I and II Interferons in Colorectal Cancer and Melanoma
Franco, S. D., Turdo, A., Todaro, M., & Stassi, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00878 · Cited by 76
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
Sui, X., Ma, J., Han, W., Wang, X., Fang, Y., Li, D., Pan, H., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5107 · Cited by 74
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 74
Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association
Wu, C.-C., Wang, Y., Livingston, J. A., Zhang, J., & Futreal, P. A. (2022) · Nature Communications · doi:10.1038/s41467-021-27651-4 · Cited by 80
Biological Hallmarks of Cancer in Alzheimer’s Disease
Nudelman, K. N. H., McDonald, B. C., Lahiri, D. K., & Saykin, A. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1591-5 · Cited by 73
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers
Beck, J. D., Diken, M., Suchan, M., Streuber, M., Diken, E., KOLB, L. D., Allnoch, L., Vascotto, F., Peters, D., Beißert, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.013 · Cited by 72
Reprogramming the tumor microenvironment to enhance adoptive cellular therapy
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Gyorki, D. E., Neeson, P. J., & Darcy, P. K. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.003 · Cited by 74
Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
Chuntova, P., Downey, K., Hegde, B., Almeida, N. D., & Okada, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03062 · Cited by 71
Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Levi, S. T., Copeland, A. R., Nah, S., Crystal, J. S., Ivey, G. D., Lalani, A., Jafferji, M. S., White, B. S., Parikh, N. B., Leko, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4499 · Cited by 72
Role of CXCR3 signaling in response to anti-PD-1 therapy
Han, X., Wang, Y., Sun, J., Tan, T., Cai, X., Lin, P., Tan, Y., Zheng, B., Wang, B., Wang, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.067 · Cited by 71
Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice
Li, T., & Wang, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07180-x · Cited by 67
Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells
Ager, A., Watson, H. A., Wehenkel, S. C., & Mohammed, R. N. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150254 · Cited by 68
Perspectives on Recent Progress in Focused Ultrasound Immunotherapy
Sheybani, N., & Price, R. J. (2019) · Theranostics · doi:10.7150/thno.37131 · Cited by 65
CXCL-10: a new candidate for melanoma therapy?
Bagheri, H., Pourhanifeh, M. H., Derakhshan, M., Mahjoubin‐Tehran, M., Ghasemi, F., Mousavi, S., Rafiei, R., Abbaszadeh‐Goudarzi, K., Mirzaei, H. R., & Mirzaei, H. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00501-z · Cited by 62
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 61
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer
Kreamer, K. M. (2014) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2014.5.6.3 · Cited by 61
Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects
Sheikh, N. A., Cham, J., Zhang, L., DeVries, T. A., Letarte, S., Pufnock, J., Hamm, D. E., Trager, J. B., & Fong, L. H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3173 · Cited by 61
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
Eißler, N., Mao, Y., Brodin, D., Reuterswärd, P., Svahn, H. A., Johnsen, J. I., Kiessling, R. W., & Kogner, P. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1232222 · Cited by 62
Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
Mohammad, G. R. K. S., Ghahremanloo, A., Soltani, A., Fathi, E., & Hashemy, S. I. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29491 · Cited by 60
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
Bessede, A., Marabelle, A., Guégan, J., Danlos, F., Cousin, S., Peyraud, F., Chaput, N., Ceruso, M. S., Roubaud, G., Cabart, M., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.010 · Cited by 59
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors
Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 62
Improving cancer immunotherapy with DNA methyltransferase inhibitors
Saleh, M. H., Wang, L., & Goldberg, M. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1776-3 · Cited by 59
The yin and yang of leukotriene B 4 mediated inflammation in cancer
Jala, V. R., Bodduluri, S. R., Satpathy, S. R., Chheda, Z. S., Sharma, R. K., & Haribabu, B. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.005 · Cited by 59
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 61
CAR T‐cell immunotherapy: The path from the by‐road to the freeway?
Whilding, L. M., & Maher, J. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.012 · Cited by 61
Negative role of inducible PD-1 on survival of activated dendritic cells
Park, S. J., Namkoong, H., Doh, J., Choi, J., Yang, B., Park, Y., & Sung, Y. C. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0813443 · Cited by 58
IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I–Deficient Tumors
Seo, H., Kim, B. S., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0708 · Cited by 59
Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
Russo, E., Santoni, A., & Bernardini, G. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0320-205r · Cited by 59
Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses
Cubas, R. A., Москаленко, М., Cheung, J., Yang, M. X., McNamara, E., Xiong, H., Hoves, S., Ries, C. H., Kim, J. G., & Gould, S. E. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800275 · Cited by 58
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 60
Targeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity
Pan, M., Wei, X., Xiang, X., Liu, Y., Zhou, Q., & Yang, W.-B. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03126-4 · Cited by 56
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
Guo, S., Contratto, M., Miller, G., Leichman, L., & Wu, J. J. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i3.230 · Cited by 57
Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment
Roussot, N., Ghiringhelli, F., & Rébé, C. (2022) · Cells · doi:10.3390/cells11223672 · Cited by 55
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors
Hamm, C. A., Moran, D. M., Rao, K., Trusk, P. B., Pry, K. J., Sausen, M., Jones, S., Velculescu, V. E., Cristofanilli, M., & Bacus, S. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0353 · Cited by 55
The anticancer peptide RT53 induces immunogenic cell death
Pasquereau-Kotula, E., Habault, J., Kroemer, G., & Poyet, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201220 · Cited by 57
T cell costimulation, checkpoint inhibitors and anti-tumor therapy
Nandi, D., Pathak, S., Verma, T., Singh, M., Chattopadhyay, A., Thakur, S., Raghavan, A., Gokhroo, A., & Vijayamahantesh, V. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-0020-2 · Cited by 58
Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy
Zhai, W., Zhou, X., Zhai, M., Li, W., Ran, Y., Sun, Y., Du, J., Zhao, W., Xing, L., Qi, Y., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1740-8 · Cited by 53
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014
Ascierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 53
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
Hu‐Lieskovan, S., & Ribas, A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000246 · Cited by 52
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 52
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
Nada, M. H., Wang, H., Workalemahu, G., Tanaka, Y., & Morita, C. T. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0209-6 · Cited by 52
Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours
Chruściel, E., Urban‐Wójciuk, Z., Arcimowicz, Ł., Kurkowiak, M., Kowalski, J., Gliwiński, M., Marjański, T., Rzyman, W., Biernat, W., Dziadziuszko, R., et al. (2020) · Cancers · doi:10.3390/cancers12030683 · Cited by 53
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 51
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade
Haymaker, C., Kim, D. W., Uemura, M. I., Vence, L. M., Phillip, A., McQuail, N., Brown, P. D., Fernandez, I., Hudgens, C. W., Creasy, C. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0223 · Cited by 49
Self-citation
Differential role of CXCR3 in inflammation and colorectal cancer
Abron, J. D., Singh, N. P., Murphy, A. E., Mishra, M. K., Price, R. L., Nagarkatti, M., Nagarkatti, P. S., & Singh, U. P. (2018) · Oncotarget · doi:10.18632/oncotarget.24730 · Cited by 48
Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma
Qian, L., Yu, S., Yin, C., Zhu, B., Chen, Z., Meng, Z., & Wang, P. (2019) · Pancreatology · doi:10.1016/j.pan.2019.01.015 · Cited by 49
Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
Taylor, J., Gandhi, A., Gray, E. S., & Zaenker, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991433 · Cited by 47
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Peng, W., Williams, L. J., Xu, C., Melendez, B., McKenzie, J. A., Chen, Y., Jackson, H. L., Voo, K. S., Mbofung, R. M., Leahey, S. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1259 · Cited by 47
Self-citation
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner
Shi, L. Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., Zhang, J., Tang, D. N., Zhang, X., Vence, L. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0873 · Cited by 47
Self-citation
Standardizing CAR-T therapy: Getting it scaled up
Dai, X., Mei, Y., Cai, D., & Han, W. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.12.002 · Cited by 47
Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
Aoki, M., Shoji, H., Nagashima, K., Imazeki, H., Miyamoto, T., Hirano, H., Honma, Y., Iwasa, S., Okita, N. T., Takashima, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000488 · Cited by 46
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation
Xiong, H., Xi, Y., Yuan, Z., Wang, B., Hu, S., Fang, C., Cai, Y., Fu, X., & Li, L. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2044103 · Cited by 48
Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment
Shan, Y., Ni, Q., Zhang, Q., Zhang, M., Wei, B., Cheng, L., Zhong, C., Wang, X., Wang, Q., Liu, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.014 · Cited by 45
IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation – a comprehensive review
Rallis, K. S., Corrigan, A. E., Dadah, H., Stanislovas, J., Zamani, P., Makker, S., Szabados, B. E., & Sideris, M. C. (2022) · Future Oncology · doi:10.2217/fon-2022-0063 · Cited by 45
Tumor-Infiltrating Lymphocyte Therapy
Radvanyi, L. G. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000162 · Cited by 45
Self-citation
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors
Bronger, H., Magdolen, V., Goettig, P., & Dreyer, T. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09807-3 · Cited by 46
Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
Ruiz‐de‐Angulo, A., Bilbao‐Asensio, M., Cronin, J., Evans, S. J., Clift, M. J. D., Llop, J., Feiner, I. V. J., Beadman, R., Zamacola, K., & Rivas, J. C. M. (2020) · iScience · doi:10.1016/j.isci.2020.101499 · Cited by 45
RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers
Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02289-2 · Cited by 44
Self-citation
T cells in the human metastatic melanoma microenvironment express site‐specific homing receptors and retention integrins
Salerno, E. P., Olson, W. C., McSkimming, C. C., Shea, S. M., & Slingluff, C. L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28391 · Cited by 44
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
Lynes, J. P., Jackson, S., Sánchez, V., Dominah, G. A., Wang, X., Kuek, A., Hayes, C. P., Benzo, S., Scott, G. C., Chittiboina, P., et al. (2018) · Neurosurgery · doi:10.1093/neuros/nyy392 · Cited by 44
Self-citation
Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
Jiang, X., Wu, H., Zhao, W., Ding, X., You, Q., Zhu, F., Qian, M., & Yu, P. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0789-y · Cited by 43
Metabolites and Immune Response in Tumor Microenvironments
Cortellino, S., & Longo, V. D. (2023) · Cancers · doi:10.3390/cancers15153898 · Cited by 43
Enhanced drug release from a pH-responsive nanocarrier can augment colon cancer treatment by blocking PD-L1 checkpoint and consuming tumor glucose
Guo, K., Liu, Y., Ding, M., Sun, Q., & Shubhra, Q. T. H. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110824 · Cited by 40
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-0968-y · Cited by 43
Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?
Karin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 41
TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10
Mauldin, I. S., Wang, E., Deacon, D. H., Olson, W. C., Bao, Y., & Slingluff, C. L. (2015) · International Journal of Cancer · doi:10.1002/ijc.29515 · Cited by 39
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells
Allegra, A., Innao, V., Gerace, D. G., Vaddinelli, D., & Musolino, C. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.11.001 · Cited by 39
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
Wanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 40
Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction
Sasmal, P., Babasahib, S. K., Kumar, B. R. P., & Raghavendra, N. M. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117001 · Cited by 39
Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
Blake, S. J., Ching, A. L. H., Kenna, T., Galea, R. C., Large, J., Yagita∥, H., & Steptoe, R. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119483 · Cited by 38
Self-citation
Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-β accumulation and improves cognition in APP/PS1 mice
Xing, Z., Zuo, Z., Hu, D., Zheng, X., Wang, X., Yuan, L., Zhou, L., Qi, F., & Yao, Z. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.09.015 · Cited by 38
Immune classification of clear cell renal cell carcinoma
Su, S., Akbarinejad, S., & Shahriyari, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-83767-z · Cited by 40
CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma
Mao, J., Li, J., Chen, J., Wen, Q., Cao, M., Zhang, F., Li, B., Zhang, Q., Wang, Z., Zhang, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007481 · Cited by 38
Self-citation
Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells
Shen, H., Sun, T., Hoang, H. H., Burchfield, J. S., Hamilton, G. F., Mittendorf, E. A., & Mauro Ferrari, B. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.002 · Cited by 37
Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy
Mehta, A., Motavaf, M., Nebo, I. D., Luyten, S., Osei-Opare, K. D., & Gru, A. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041200 · Cited by 38
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
Peng, W., Lizee, G. A., & Hwu, P. (2013) · OncoImmunology · doi:10.4161/onci.22691 · Cited by 36
Self-citation
Vaccine-Elicited CD8+ T Cells Cure Mesothelioma by Overcoming Tumor-Induced Immunosuppressive Environment
Tan, Z., Zhou, J., Cheung, A. K. L., Yu, Z., Cheung, K., Liang, J., Wang, H., Lee, B. K., Man, K., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0473 · Cited by 36
Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa
Chen, Y., Li, Q., Li, X., Ma, D., Fang, J., Luo, L., Liu, X., Wang, X., Lui, V. W. Y., Xia, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1388484 · Cited by 36
Hyperprogressive Disease in Hepatocellular Carcinoma with Immune Checkpoint Inhibitor Use: A Case Series
Wong, D. J., Lee, J. J. X., Choo, S. P., Thng, C. H., & Hennedige, T. P. (2019) · Immunotherapy · doi:10.2217/imt-2018-0126 · Cited by 36
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
Ji, Z., Peng, Z., Gong, J., Zhang, X., Li, J., Lu, M. S., Lü, Z., & Shen, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5921-9 · Cited by 36
RETRACTED: How microRNAs affect the PD-L1 and its synthetic pathway in cancer
Danbaran, G. R., Aslani, S., Sharafkandi, N., Hemmatzadeh, M., Hosseinzadeh, R., Azizi, G., Jadidi‐Niaragh, F., Babaie, F., & Mohammadi, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106594 · Cited by 36
Retracted
Cytokines that target immune killer cells against tumors
Qiao, J., & Fu, Y. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0481-0 · Cited by 36
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 36
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
Galluzzi, L., Kroemer, G., & Eggermont, A. M. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.967147 · Cited by 39
Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies
Borch, T. H., Donia, M., Andersen, M. H., & Svane, I. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.003 · Cited by 35
Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma
LaPorte, J., Solh, M., & Ouanounou, S. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215620922 · Cited by 35
Striking a Balance—Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation
Hope, J. L., Stairiker, C. J., Bae, E., Otero, D. C., & Bradley, L. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01595 · Cited by 38

Authors: Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., & Hwu, P.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Authors' Affiliations: 1Department of Melanoma Medical Oncology, The Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan
Corresponding author: Hwu, Patrick
ORCID: Peng, Weiyi
Liu, Chengwen
Xu, Chunyu
Lou, Yanyan
Chen, Jieqing
Yang, Yan
Radvanyi, Laszlo
Hwu, Patrick
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-10-14
Volume: 72
Issue: 20
Pages: 5209-5218
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-12-1187
PMC: PMC3476734
OpenAlex: W2116158418
Cited by: 432
References: 41
Citations by year: 2026: 18 · 2025: 25 · 2024: 27 · 2023: 38 · 2022: 47 · 2021: 31 · 2020: 30 · 2019: 40 · 2018: 38 · 2017: 34 · 2016: 33 · 2015: 34 · 2014: 17 · 2013: 18 · 2012: 2
FWCI: 11.23
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Japan Society for the Promotion of Science (22240089)
National Cancer Institute (R01CA143077, CA 016672, R01CA123182, P01CA128913, R01CA116206, P30CA016672)
National Center for Research Resources (UL1RR024148)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: anti-PD-1 therapy, adoptive cell transfer, interferon-gamma, CXCL10, chemokines, tumor microenvironment, regulatory T cells, myeloid-derived suppressor cells, IFN-gamma receptor, antitumor immunity, immune cell trafficking
MeSH terms: Animals, Cell Movement, Interferon-gamma, Mice, Transgenic, Neoplasms, Experimental, T-Lymphocytes, Up-Regulation, Lymphocytes, Tumor-Infiltrating, Chemokines, Adoptive Transfer, Cell Proliferation, Mice, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks